Arcellx Acquired by Gilead Sciences | Healthcare M&A Deal

Gilead Sciences has completed the acquisition of Arcellx, a medical devices business in California, for $7.8 billion. Arcellx develops CAR T therapy anito-cel, supporting cell-based oncology treatment for patients with hematologic cancers. Gilead Sciences acquires Arcellx to secure full control of its CAR T pipeline and expand healthcare M&A capabilities in advanced immunotherapy. The strategic acquisition is structured as a merger acquisition and is categorized as a healthcare M&A deal with closed status and over $100M value.